Bioasis Technologies (TSXV:BTI) Total Payout Ratio : 0.00 (As of Jun. 08, 2024)

View and export this data going back to 2007. Start your Free Trial

What is Bioasis Technologies Total Payout Ratio?

Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income.

Bioasis Technologies's current Total Payout Ratio is 0.00.

Bioasis Technologies Total Payout Ratio Historical Data

The historical data trend for Bioasis Technologies's Total Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bioasis Technologies Total Payout Ratio Chart

Bioasis Technologies Annual Data

Trend

Feb13

Feb14

Feb15

Feb16

Feb17

Feb18

Feb19

Feb20

Feb21

Feb22

Total Payout Ratio

Get a 7-Day Free Trial

0.74

1.02

0.30

-0.28

0.07

Bioasis Technologies Quarterly Data
	Feb18	May18	Aug18	Nov18	Feb19	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22
Total Payout Ratio	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Bioasis Technologies's Total Payout Ratio

For the Biotechnology subindustry, Bioasis Technologies's Total Payout Ratio, along with its competitors' market caps and Total Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bioasis Technologies's Total Payout Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bioasis Technologies's Total Payout Ratio distribution charts can be found below:

* The bar in red indicates where Bioasis Technologies's Total Payout Ratio falls into.

Bioasis Technologies Total Payout Ratio Calculation

Total Payout Ratio is a measurement showing the proportion of earnings a company pays shareholders in the form of dividends and net stock repurchases.

Bioasis Technologies's Total Payout Ratio for the fiscal year that ended in Feb. 2022 is calculated as

Total Payout Ratio	=	- (Repurchase of Stock	+	Issuance of Stock	+	Cash Flow for Dividends)	/	Net Income
	=	- (0	+	0.196	+	0)	/	-2.96
	=	0.07

Bioasis Technologies's Total Payout Ratio for the quarter that ended in Nov. 2022 is calculated as

Total Payout Ratio	=	- (Repurchase of Stock	+	Issuance of Stock	+	Cash Flow for Dividends)	/	Net Income
	=	- (0	+	0	+	0)	/	-0.986
	=	0.00

Bioasis Technologies Total Payout Ratio Related Terms

Thank you for viewing the detailed overview of Bioasis Technologies's Total Payout Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Bioasis Technologies (TSXV:BTI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bioasis Technologies Inc (TSXV:BTI) » Definitions » Total Payout Ratio

Comparable Companies

Traded in Other Exchanges

N/A

Address

157 Church Street, 19th Floor, New Haven, CT, USA, 06510

Website

https://www.bioasis.us

Bioasis Technologies Inc is a development stage biopharmaceutical company. It is engaged in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. The company has worked on a blood-brain barrier program and studies disorders in the brain. The company's xB3 program describes its proprietary carrier, for the delivery of therapeutics across the blood-brain barrier and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases. The company's in-house development programs are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders.